Honokiol

Honokiol (3',5-di-2-propenyl-1,1'-biphenyl-2,4'-diol) is a biphenyl neolignan polyphenol isolated principally from the bark, seed cones, and leaves of Magnolia officinalis and related species of the genus Magnolia, a botanical source with documented use in traditional Chinese, Japanese, and Korean medicine for over two thousand years. The compound has attracted substantial modern pharmacological interest owing to a pleiotropic mechanism profile that includes positive allosteric modulation of both synaptic and extrasynaptic GABAA receptors at a site distinct from the benzodiazepine binding site; direct activation of the mitochondrial deacetylase sirtuin-3 (SIRT3) with consequent enhancement of mitochondrial respiration, ATP production, and antioxidant defense; agonism at peroxisome proliferator-activated receptor gamma (PPARgamma); inhibition of nuclear factor kappa-B (NF-kB) and signal transducer and activator of transcription 3 (STAT3) signaling; modulation of the PI3K/Akt/mTOR axis; and disruption of the PSD95-nNOS protein-protein interaction at glutamatergic synapses. The preclinical pharmacology of honokiol spans four principal domains. In oncology, honokiol inhibits proliferation, induces apoptosis through both intrinsic and extrinsic pathways, suppresses angiogenesis, and reduces metastatic potential in cell-line and xenograft models of breast, colon, prostate, lung, glioblastoma, and hematological malignancies, with demonstrated activity against NF-kB, STAT3, EGFR, and survivin signaling. In neuroprotection, honokiol preserves neuronal viability against amyloid-beta toxicity, glutamate excitotoxicity, and oxidative insult through SIRT3-dependent mitochondrial stabilization, reduction of reactive oxygen species, suppression of intracellular calcium elevation, and inhibition of caspase-3 activation. In anxiolysis and sedation, honokiol potentiates GABAergic neurotransmission at concentrations below those required for overt sedation, producing anxiolytic-like behavioral effects in rodent models without the tolerance, dependence, and amnesia liabilities associated with classical benzodiazepines. In inflammation, honokiol suppresses NF-kB-driven proinflammatory cytokine release, reduces glial activation in cerebral ischemia-reperfusion models, and attenuates inflammatory markers in models of sepsis, diabetic nephropathy, and postoperative cognitive decline. Pharmacokinetics in rodents are characterized by rapid oral absorption (time to peak plasma concentration approximately 20 minutes at 40 mg/kg in rats), extensive hepatic first-pass metabolism via glucuronidation and sulfation as the dominant biotransformation pathways, and limited oral bioavailability (reported values range from approximately 5 to 23 percent depending on formulation and species). The compound readily crosses the blood-brain barrier, a property that distinguishes it from many polyphenols of comparable molecular weight and that supports the observed central nervous system effects. The elimination half-life in rats after intravenous administration is approximately 49 to 56 minutes at doses of 5 to 10 mg/kg. The principal circulating species after oral administration is the monoglucuronide conjugate rather than free honokiol. Clinical evidence in humans is limited. A Phase I trial of liposomal honokiol in patients with relapsed or progressed malignant glioma reported safety, tolerability, and preliminary survival benefit with a dose-response relationship. Phase II trials of liposomal honokiol are ongoing in China. Magnolia bark extract containing honokiol has been evaluated in human supplementation trials at doses up to 500 mg daily for up to one year without reported adverse effects, though these preparations contain variable ratios of honokiol and its isomer magnolol. No regulatory authority has approved honokiol as a pharmaceutical agent. The compound is available as a dietary supplement ingredient in several jurisdictions and as a research-grade chemical from multiple suppliers. Investigators should obtain analytical confirmation of identity, purity, and honokiol-to-magnolol ratio on every lot. This monograph reviews the chemistry, isolation, and synthesis of honokiol; the multi-target molecular pharmacology in detail; the comprehensive rodent pharmacokinetic record; the preclinical pharmacology across oncology, neuroprotection, anxiolysis, and inflammation; the limited clinical evidence base; sourcing and quality verification considerations; reconstitution and handling; stack-interaction implications; adverse-event and safety signal; and a comparative assessment of five alternative compounds (magnolol, baicalein, resveratrol, curcumin, dihydrohonokiol-B) against honokiol on five competency standards.